Nicole D. Ford
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Nicole D. Ford has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
Sharon Saydah
Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia
7 shared publications- Sharon Saydah
Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia
6 shared publications Maria Elena Jefferds
Nutrition Branch, Division of Nutrition, Physical Activity, and Obesity, US Centers for Disease Control and Prevention , Atlanta, GA 30341, USA
5 shared publicationsAbdelrahman Lubowa
School of Food Technology, Nutrition, and Bioengineering, Makerere University , Kampala, Uganda
4 shared publicationsAlexandra F. Dalton
Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases CDC Atlanta Georgia USA
4 shared publications- Alexandra F. Dalton
Coronavirus & Other Respiratory Viruses Division (CORVD), National Center for Immunization and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention (CDC), 1600 Clifton Rd., NE, Mailstop US1-1, Atlanta, GA 30329-4027, USA
4 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (11) , e0345433
Long COVID prevalence among U.S. adults: A state-level ecological analysis of associations with SARS-CoV-2 incidence, COVID-19 hospitalization rates, COVID-19 vaccine coverage, and multimorbidity
Background: Long COVID has emerged as a major public health concern in the United States, yet geographic variation in its prevalence remains poorly understood. This study examines how state-level differences in COVID-19 vaccination, SARS-CoV-2 infection burden, severity of acute COVID-19 (measured by hospitalization rates) and multimorbidity burden relate to adult Long COVID prevalence in the United States. Methods: We conducted an ecological analysis using data from the 2023 Behavioral Risk Factor Surveillance System (BRFSS), from which we estimated state-level prevalence of self-reported Long COVID among adults. These estimates were linked with publicly available data on SARS-CoV-2 incidence, COVID-19 hospitalizations, COVID-19 vaccine coverage, and a multimorbidity indicator (defined as ≥3 chronic conditions associated with increased risk of severe COVID-19, e.g., diabetes, obesity, chronic kidney disease). Multivariable linear regression models were used to assess the association between these factors and Long COVID prevalence, adjusting for state age and sex distributions. Rubin’s rules were applied to propagate the uncertainty in the estimates of Long COVID and COVID-19 vaccine coverage through regression analyses. Results: All examined factors—including SARS-CoV-2 incidence, COVID-19 hospitalization, COVID-19 vaccine coverage, and multimorbidity prevalence—varied by state. In univariable analyses, vaccine coverage and multimorbidity prevalence were significantly associated with Long COVID prevalence. In the multivariable model, vaccine coverage and SARS-CoV-2 incidence were significant; however, after accounting for uncertainty in Long COVID and vaccine coverage estimates, only higher vaccine coverage remained significantly associated with lower Long COVID prevalence. Conclusions: Higher State-level variation in COVID-19 vaccine coverage was consistently associated with lower adult Long COVID prevalence. These ecological findings support further investigation of vaccination and other state-level determinants of Long COVID burden and may inform population-level strategies for addressing Long COVID.
- 3 November 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (11) , e0345433
Open AccessLong COVID prevalence among U.S. adults: A state-level ecological analysis of associations with SARS-CoV-2 incidence, COVID-19 hospitalization rates, COVID-19 vaccine coverage, and multimorbidity
Background: Long COVID has emerged as a major public health concern in the United States, yet geographic variation in its prevalence remains poorly understood. This study examines how state-level differences in COVID-19 vaccination, SARS-CoV-2 infection burden, severity of acute COVID-19 (measured by hospitalization rates) and multimorbidity burden relate to adult Long COVID prevalence in the United States. Methods: We conducted an ecological analysis using data from the 2023 Behavioral Risk Factor Surveillance System (BRFSS), from which we estimated state-level prevalence of self-reported Long COVID among adults. These estimates were linked with publicly available data on SARS-CoV-2 incidence, COVID-19 hospitalizations, COVID-19 vaccine coverage, and a multimorbidity indicator (defined as ≥3 chronic conditions associated with increased risk of severe COVID-19, e.g., diabetes, obesity, chronic kidney disease). Multivariable linear regression models were used to assess the association between these factors and Long COVID prevalence, adjusting for state age and sex distributions. Rubin’s rules were applied to propagate the uncertainty in the estimates of Long COVID and COVID-19 vaccine coverage through regression analyses. Results: All examined factors—including SARS-CoV-2 incidence, COVID-19 hospitalization, COVID-19 vaccine coverage, and multimorbidity prevalence—varied by state. In univariable analyses, vaccine coverage and multimorbidity prevalence were significantly associated with Long COVID prevalence. In the multivariable model, vaccine coverage and SARS-CoV-2 incidence were significant; however, after accounting for uncertainty in Long COVID and vaccine coverage estimates, only higher vaccine coverage remained significantly associated with lower Long COVID prevalence. Conclusions: Higher State-level variation in COVID-19 vaccine coverage was consistently associated with lower adult Long COVID prevalence. These ecological findings support further investigation of vaccination and other state-level determinants of Long COVID burden and may inform population-level strategies for addressing Long COVID.
- Open Access
Worsening pre-existing health conditions in U.S. adults with Long COVID
Purpose: Long COVID literature often describes new-onset symptoms or conditions following SARS-CoV-2 infection; however, Long COVID also encompasses the exacerbation of pre-existing conditions. We describe health conditions reportedly worsened by COVID-19 illness and associated concerns in U.S. adults. Methods: We collected longitudinal data from adults 18 years and older participating in the Track Post COVID-19 Conditions, an active Long COVID cohort surveillance project. Respondents completed surveys 3-, 6-, and 12- months after COVID-19 illness, beginning in July 2023. In each survey, respondents were asked whether they had any health conditions or concerns that were made worse by COVID-19. Those with an affirmative response were asked to specify the worsening condition(s) via free text. Some respondents used this free text to describe challenges or experiences related to their worsening conditions. This report categorizes and quantifies reported conditions and concerns by body system categories and qualitatively describes associated challenges and experiences using direct quotes from respondents’ free text responses. Results: Among 2,227 adults, 263 (11.8%) respondents reported at least one worsening condition or concern following COVID-19 illness. Of these, nearly 32% reported a worsening respiratory condition or concern. Adults with worsening pre-existing conditions reported challenges accessing adequate care, completing daily activities, and managing their symptoms following COVID-19. Discussion: While Long COVID literature often focuses on the development of new-onset long-term symptoms, more than 1 in 10 adults reported worsening of a pre-existing condition following COVID-19. Reported challenges with accessing care and daily activities highlight potential need for accommodations or support for adults with Long COVID.
Open AccessWorsening pre-existing health conditions in U.S. adults with Long COVID
Purpose: Long COVID literature often describes new-onset symptoms or conditions following SARS-CoV-2 infection; however, Long COVID also encompasses the exacerbation of pre-existing conditions. We describe health conditions reportedly worsened by COVID-19 illness and associated concerns in U.S. adults. Methods: We collected longitudinal data from adults 18 years and older participating in the Track Post COVID-19 Conditions, an active Long COVID cohort surveillance project. Respondents completed surveys 3-, 6-, and 12- months after COVID-19 illness, beginning in July 2023. In each survey, respondents were asked whether they had any health conditions or concerns that were made worse by COVID-19. Those with an affirmative response were asked to specify the worsening condition(s) via free text. Some respondents used this free text to describe challenges or experiences related to their worsening conditions. This report categorizes and quantifies reported conditions and concerns by body system categories and qualitatively describes associated challenges and experiences using direct quotes from respondents’ free text responses. Results: Among 2,227 adults, 263 (11.8%) respondents reported at least one worsening condition or concern following COVID-19 illness. Of these, nearly 32% reported a worsening respiratory condition or concern. Adults with worsening pre-existing conditions reported challenges accessing adequate care, completing daily activities, and managing their symptoms following COVID-19. Discussion: While Long COVID literature often focuses on the development of new-onset long-term symptoms, more than 1 in 10 adults reported worsening of a pre-existing condition following COVID-19. Reported challenges with accessing care and daily activities highlight potential need for accommodations or support for adults with Long COVID.
- Open Access
Social Determinants of Health and Long COVID in U.S. Children: A Cross-Sectional Study, 2022--2023
Objective: We characterized social determinants of health (SDOH) in U.S. children who ever and never had Long COVID. Methods: We used cross-sectional data from the 2022-2023 National Health Interview Survey (N=14,993 children 0-17 years). Parents reported child- and household-level information. Long COVID was defined as ever experiencing symptoms lasting ≥3 months that were not present prior to having COVID-19. We produced weighted prevalence estimates by Long COVID status for 3 SDOH domains (Social and Community Context, Healthcare Access and Quality, and Economic Stability) and used Rao-Scott chi-squared tests to examine differences. Results: In Social and Community Context, children who ever had Long COVID more often resided in single parent households (33.2% vs. 20.3%; p<0.0001), with someone with severe depression or mental illness (18.5% vs. 8.3%; p<0.0001) or substance abuse (16.7% vs. 8.1%; p<0.0001) or had a lifetime of being disparaged by adults in the home (9.2% vs. 3.9%; p=0.0009). In Healthcare Access and Quality, children who ever had Long COVID more often had public insurance (e.g., Medicaid) (51.3% vs. 41.6%; p=0.02), higher healthcare use, and difficulty paying medical bills (23.2% vs. 12.2%; p<0.0001). In Economic Stability, children who ever had Long COVID had lower parental education, lower food security, and higher participation in social safety net programs (p<0.01 for all comparisons). Conclusion: Children who ever had Long COVID more frequently experienced adverse SDOH compared to their peers who never had Long COVID. These findings may help identify children who may benefit from additional resources related to their Long COVID care. Article Summary: Children who had Long COVID more frequently reported adverse Social Determinants of Health (SDOH) compared to their peers who never had Long COVID. What’s Known on This Subject: The relationship of SDOH and Long COVID in children has not been well characterized; however, research indicates potential disparities in Long COVID symptoms and severity based on age, sex, race, ethnicity, and socioeconomic characteristics. What This Study Adds: In a nationally representative sample, we found that U.S. children who had Long COVID more frequently reported adverse SDOH. These results may help identify higher-risk children who may benefit from additional resources related to their Long COVID care.
Open AccessSocial Determinants of Health and Long COVID in U.S. Children: A Cross-Sectional Study, 2022--2023
Objective: We characterized social determinants of health (SDOH) in U.S. children who ever and never had Long COVID. Methods: We used cross-sectional data from the 2022-2023 National Health Interview Survey (N=14,993 children 0-17 years). Parents reported child- and household-level information. Long COVID was defined as ever experiencing symptoms lasting ≥3 months that were not present prior to having COVID-19. We produced weighted prevalence estimates by Long COVID status for 3 SDOH domains (Social and Community Context, Healthcare Access and Quality, and Economic Stability) and used Rao-Scott chi-squared tests to examine differences. Results: In Social and Community Context, children who ever had Long COVID more often resided in single parent households (33.2% vs. 20.3%; p<0.0001), with someone with severe depression or mental illness (18.5% vs. 8.3%; p<0.0001) or substance abuse (16.7% vs. 8.1%; p<0.0001) or had a lifetime of being disparaged by adults in the home (9.2% vs. 3.9%; p=0.0009). In Healthcare Access and Quality, children who ever had Long COVID more often had public insurance (e.g., Medicaid) (51.3% vs. 41.6%; p=0.02), higher healthcare use, and difficulty paying medical bills (23.2% vs. 12.2%; p<0.0001). In Economic Stability, children who ever had Long COVID had lower parental education, lower food security, and higher participation in social safety net programs (p<0.01 for all comparisons). Conclusion: Children who ever had Long COVID more frequently experienced adverse SDOH compared to their peers who never had Long COVID. These findings may help identify children who may benefit from additional resources related to their Long COVID care. Article Summary: Children who had Long COVID more frequently reported adverse Social Determinants of Health (SDOH) compared to their peers who never had Long COVID. What’s Known on This Subject: The relationship of SDOH and Long COVID in children has not been well characterized; however, research indicates potential disparities in Long COVID symptoms and severity based on age, sex, race, ethnicity, and socioeconomic characteristics. What This Study Adds: In a nationally representative sample, we found that U.S. children who had Long COVID more frequently reported adverse SDOH. These results may help identify higher-risk children who may benefit from additional resources related to their Long COVID care.
- Open Access
Long COVID Prevalence among U.S. Adults: A State-level Ecological Analysis of the Contribution of COVID-19 Incidence, Severity of Acute Illness, COVID-19 Vaccination, and Chronic Conditions
Background: Long COVID has emerged as a major public-health concern in the United States, yet geographic variation in its prevalence remains poorly understood. This study examines how state-level differences in COVID-19 vaccination, SARS-CoV-2 incidence, COVID-19 hospitalization, and chronic disease burden relate to adult Long COVID prevalence in the United States. Methods: We conducted an ecological analysis using data from the 2023 Behavioral Risk Factor Surveillance System (BRFSS), from which we estimated state-level prevalence of self-reported Long COVID among adults. These estimates were linked with publicly available data on SARS-CoV-2 incidence, COVID-19 hospitalizations, COVID-19 vaccine coverage, and a multimorbidity indicator (>= 3 chronic conditions e.g., diabetes, obesity, chronic kidney disease) associated with higher risk for severe SARS-CoV-2. Multivariable linear regression models were fitted to assess the contribution of each factor adjusted for age and sex distribution, incorporating Rubin’s rules to account for uncertainty in prevalence estimates. Results: All examined factors—including SARS-CoV-2 incidence, hospitalization rates, and multimorbidity, vaccine coverage—varied by state. When modeled simultaneously and adjusting for age and sex distribution, only COVID-19 vaccine coverage and SARS-CoV-2 incidence were significantly associated with Long COVID prevalence. COVID-19 vaccine coverage showed a strong protective association, while SARS-CoV-2 incidence showed a modest positive association. Multimorbidity and hospitalization rates were not independently associated with adjustment. Conclusions: State-level variation in Long COVID burden appears most strongly driven by COVID-19 vaccine coverage and SARS-CoV-2 incidence. Promoting COVID-19 vaccination remains essential to reduce long-term impacts from SARS-CoV-2 infections.
Open AccessLong COVID Prevalence among U.S. Adults: A State-level Ecological Analysis of the Contribution of COVID-19 Incidence, Severity of Acute Illness, COVID-19 Vaccination, and Chronic Conditions
Background: Long COVID has emerged as a major public-health concern in the United States, yet geographic variation in its prevalence remains poorly understood. This study examines how state-level differences in COVID-19 vaccination, SARS-CoV-2 incidence, COVID-19 hospitalization, and chronic disease burden relate to adult Long COVID prevalence in the United States. Methods: We conducted an ecological analysis using data from the 2023 Behavioral Risk Factor Surveillance System (BRFSS), from which we estimated state-level prevalence of self-reported Long COVID among adults. These estimates were linked with publicly available data on SARS-CoV-2 incidence, COVID-19 hospitalizations, COVID-19 vaccine coverage, and a multimorbidity indicator (>= 3 chronic conditions e.g., diabetes, obesity, chronic kidney disease) associated with higher risk for severe SARS-CoV-2. Multivariable linear regression models were fitted to assess the contribution of each factor adjusted for age and sex distribution, incorporating Rubin’s rules to account for uncertainty in prevalence estimates. Results: All examined factors—including SARS-CoV-2 incidence, hospitalization rates, and multimorbidity, vaccine coverage—varied by state. When modeled simultaneously and adjusting for age and sex distribution, only COVID-19 vaccine coverage and SARS-CoV-2 incidence were significantly associated with Long COVID prevalence. COVID-19 vaccine coverage showed a strong protective association, while SARS-CoV-2 incidence showed a modest positive association. Multimorbidity and hospitalization rates were not independently associated with adjustment. Conclusions: State-level variation in Long COVID burden appears most strongly driven by COVID-19 vaccine coverage and SARS-CoV-2 incidence. Promoting COVID-19 vaccination remains essential to reduce long-term impacts from SARS-CoV-2 infections.
- 30 August 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (2) , e352-e362
Prevalence of Symptoms Associated With Long COVID Among Adolescents in the United States, Summer 2022
Background: Limited information is known about long COVID among adolescents. This study compared the risks associated with symptoms among adolescents who tested positive, were tested but never tested positive, or who were never tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Methods: Porter Novelli survey data were collected from adolescents (aged 12–17 years) from 31 May 31 through 6 July 2022. Respondents self-reported their SARS-CoV-2 test results and were classified accordingly by test status. Wald χ2 tests were used to determine whether demographic factors and characteristics related to symptoms differed by test status. Multivariable logistic regression models were used to estimate the odds of reporting (1) symptoms lasting 4 weeks or longer and (2) symptoms lasting 3 or more months by test status and SARS-CoV-2 variant period. Results: Data were collected from 784 respondents: 264 (34%) tested positive, 291 (37%) never tested positive, and 229 (29%) were never tested for SARS-CoV-2 infection. At least 1 symptom lasting ≥4 weeks was reported by 41% of the positive respondents, compared to 12% of negative respondents and 11% of never tested respondents (P < .05). The odds of reporting at least 1 symptom lasting ≥4 weeks did not vary by SARS-CoV-2 variant period. Adolescents who tested positive had increased odds of any neurological symptom lasting ≥3 months compared to negative adolescents. Conclusions: Our results demonstrate that adolescents who tested positive for SARS-CoV-2 were more likely to report at least 1 symptom lasting for at least 4 weeks. However, most of these symptoms appeared to have resolved within 3 months.
- 30 August 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (2) , e352-e362
Prevalence of Symptoms Associated With Long COVID Among Adolescents in the United States, Summer 2022
Background: Limited information is known about long COVID among adolescents. This study compared the risks associated with symptoms among adolescents who tested positive, were tested but never tested positive, or who were never tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Methods: Porter Novelli survey data were collected from adolescents (aged 12–17 years) from 31 May 31 through 6 July 2022. Respondents self-reported their SARS-CoV-2 test results and were classified accordingly by test status. Wald χ2 tests were used to determine whether demographic factors and characteristics related to symptoms differed by test status. Multivariable logistic regression models were used to estimate the odds of reporting (1) symptoms lasting 4 weeks or longer and (2) symptoms lasting 3 or more months by test status and SARS-CoV-2 variant period. Results: Data were collected from 784 respondents: 264 (34%) tested positive, 291 (37%) never tested positive, and 229 (29%) were never tested for SARS-CoV-2 infection. At least 1 symptom lasting ≥4 weeks was reported by 41% of the positive respondents, compared to 12% of negative respondents and 11% of never tested respondents (P < .05). The odds of reporting at least 1 symptom lasting ≥4 weeks did not vary by SARS-CoV-2 variant period. Adolescents who tested positive had increased odds of any neurological symptom lasting ≥3 months compared to negative adolescents. Conclusions: Our results demonstrate that adolescents who tested positive for SARS-CoV-2 were more likely to report at least 1 symptom lasting for at least 4 weeks. However, most of these symptoms appeared to have resolved within 3 months.
- 18 August 2025
- Published by Wiley in American Journal of Industrial Medicine
- Vol. 68 (10) , 909-919
Employment Status, Work Limitations, Cognitive Dysfunction, and Sickness Absenteeism Among US Adults With and Without Long COVID
Introduction: Long COVID may limit people's ability to carry out daily activities, including work. Little is known about the potential effect of long COVID on work limitations and absenteeism. We describe employment status and characteristics, work limitations, cognitive dysfunction, and sickness absenteeism among adults with and without long COVID. Methods: Using data from the cross‐sectional 2022 National Health Interview Survey, we estimated the prevalence (95% confidence intervals [CI]) of work‐related outcomes by long COVID status among US adults ≥ 18 years ( n = 26,270). Among employed adults with prior COVID‐19 illness, we estimated crude and adjusted odds ratios for work limitations (compared to no limitations), cognitive dysfunction (some or a lot of difficulty with memory or concentration compared to no difficulty), and sickness absenteeism ( ≥ 11 sick days compared to 0–10 days) in the prior year. All estimates account for survey design and are weighted to the US noninstitutionalized population. Analyses were conducted in 2024. Results: 3.4% of adults reported long COVID. Adults with long COVID more often reported being unable to work due to health or disability compared to adults without long COVID ( p = 0.0006). Among employed adults with prior COVID‐19 illness, long COVID was associated with higher odds of work limitations (aOR 1.3, 95% CI 1.1–1.5), cognitive dysfunction (aOR 1.3, 95% CI 1.1–1.5), and sickness absenteeism (aOR 1.4, 95% CI 1.2–1.5) compared to those who did not develop long COVID. Conclusions: Long COVID was associated with work limitations, cognitive dysfunction, and sickness absenteeism among employed US adults. Workplace accommodations may be important considerations for people with long COVID.
- 18 August 2025
- Published by Wiley in American Journal of Industrial Medicine
- Vol. 68 (10) , 909-919
Employment Status, Work Limitations, Cognitive Dysfunction, and Sickness Absenteeism Among US Adults With and Without Long COVID
Introduction: Long COVID may limit people's ability to carry out daily activities, including work. Little is known about the potential effect of long COVID on work limitations and absenteeism. We describe employment status and characteristics, work limitations, cognitive dysfunction, and sickness absenteeism among adults with and without long COVID. Methods: Using data from the cross‐sectional 2022 National Health Interview Survey, we estimated the prevalence (95% confidence intervals [CI]) of work‐related outcomes by long COVID status among US adults ≥ 18 years ( n = 26,270). Among employed adults with prior COVID‐19 illness, we estimated crude and adjusted odds ratios for work limitations (compared to no limitations), cognitive dysfunction (some or a lot of difficulty with memory or concentration compared to no difficulty), and sickness absenteeism ( ≥ 11 sick days compared to 0–10 days) in the prior year. All estimates account for survey design and are weighted to the US noninstitutionalized population. Analyses were conducted in 2024. Results: 3.4% of adults reported long COVID. Adults with long COVID more often reported being unable to work due to health or disability compared to adults without long COVID ( p = 0.0006). Among employed adults with prior COVID‐19 illness, long COVID was associated with higher odds of work limitations (aOR 1.3, 95% CI 1.1–1.5), cognitive dysfunction (aOR 1.3, 95% CI 1.1–1.5), and sickness absenteeism (aOR 1.4, 95% CI 1.2–1.5) compared to those who did not develop long COVID. Conclusions: Long COVID was associated with work limitations, cognitive dysfunction, and sickness absenteeism among employed US adults. Workplace accommodations may be important considerations for people with long COVID.
- 17 July 2025
- Published by Wolters Kluwer Health in Journal of Public Health Management & Practice
- Vol. 31 (5) , E292-E302
Use and Characteristics of Clinical Coding for Post-COVID Conditions in a Retrospective US Cohort
Context: Little is known about when and how the ICD-10-CM diagnosis code for Post-COVID Conditions (PCC; U09.9) is being used to document PCC. Objectives: To examine the use and characteristics of clinical coding for PCC. Design: A retrospective cohort. Setting: Transaction-level medical encounters, laboratory testing results, pharmacy claims, and medical claims for inpatient and outpatient care from the HealthVerity database. Participants: 382 400 US adults and children with private health insurance, Medicare, and Medicaid who had U09.9 code documented during October 1, 2021-June 30, 2023. Outcome Measures: Count of first use of the U09.9 code, (a) overall, over time, and proportion by provider type; (b) prevalence of PCC-associated incident conditions co-documented with U09.9; (c) number of documented SARS-CoV-2 infections preceding U09.9; (d) timing between infection and U09.9; (e) encounters during the 6 months following first use of U09.9. Results: Overall, 0.6% of 65 556 068 patients had a PCC diagnosis code (64.6% female; 6 in 10 had ≥1 preexisting conditions). The highest count of new U09.9 codes occurred during Quarter 1 and Quarter 3 of 2022 and was documented by a variety of provider specialties. The most prevalent co-documented PCC-associated incident conditions were respiratory (13.4%) and malaise and fatigue (7.8%). Only 62% of patients had SARS-CoV-2 infection documented preceding U09.9; median time to PCC documentation was 17.0 days (interquartile range [IQR] = 5.0, 61.0). Patients with ≥1 encounters during which PCC was documented in the 6 months following their index encounter (n = 109 794) had, on average, 25.5 additional encounters (median = 14 [IQR = 7, 29]). Conclusions: Our study describes the sociodemographic characteristics, complex clinical manifestations, and high healthcare use of patients following a PCC diagnosis. These findings may inform efforts to identify and treat PCC, inform healthcare planning, and support efforts to educate clinicians about the definition of PCC and accurate application of the code.
- 17 July 2025
- Published by Wolters Kluwer Health in Journal of Public Health Management & Practice
- Vol. 31 (5) , E292-E302
Use and Characteristics of Clinical Coding for Post-COVID Conditions in a Retrospective US Cohort
Context: Little is known about when and how the ICD-10-CM diagnosis code for Post-COVID Conditions (PCC; U09.9) is being used to document PCC. Objectives: To examine the use and characteristics of clinical coding for PCC. Design: A retrospective cohort. Setting: Transaction-level medical encounters, laboratory testing results, pharmacy claims, and medical claims for inpatient and outpatient care from the HealthVerity database. Participants: 382 400 US adults and children with private health insurance, Medicare, and Medicaid who had U09.9 code documented during October 1, 2021-June 30, 2023. Outcome Measures: Count of first use of the U09.9 code, (a) overall, over time, and proportion by provider type; (b) prevalence of PCC-associated incident conditions co-documented with U09.9; (c) number of documented SARS-CoV-2 infections preceding U09.9; (d) timing between infection and U09.9; (e) encounters during the 6 months following first use of U09.9. Results: Overall, 0.6% of 65 556 068 patients had a PCC diagnosis code (64.6% female; 6 in 10 had ≥1 preexisting conditions). The highest count of new U09.9 codes occurred during Quarter 1 and Quarter 3 of 2022 and was documented by a variety of provider specialties. The most prevalent co-documented PCC-associated incident conditions were respiratory (13.4%) and malaise and fatigue (7.8%). Only 62% of patients had SARS-CoV-2 infection documented preceding U09.9; median time to PCC documentation was 17.0 days (interquartile range [IQR] = 5.0, 61.0). Patients with ≥1 encounters during which PCC was documented in the 6 months following their index encounter (n = 109 794) had, on average, 25.5 additional encounters (median = 14 [IQR = 7, 29]). Conclusions: Our study describes the sociodemographic characteristics, complex clinical manifestations, and high healthcare use of patients following a PCC diagnosis. These findings may inform efforts to identify and treat PCC, inform healthcare planning, and support efforts to educate clinicians about the definition of PCC and accurate application of the code.
- 1 April 2025
- Published by American Medical Association (AMA) in JAMA Pediatrics
- Vol. 179 (4) , 471-473
Long COVID Prevalence and Associated Activity Limitation in US Children
This cross-sectional study estimates ever and current experiences of lasting COVID-19 symptoms among children and adolescents by sociodemographic characteristics.
- 1 April 2025
- Published by American Medical Association (AMA) in JAMA Pediatrics
- Vol. 179 (4) , 471-473
Long COVID Prevalence and Associated Activity Limitation in US Children
This cross-sectional study estimates ever and current experiences of lasting COVID-19 symptoms among children and adolescents by sociodemographic characteristics.
- Open Access
- 1 January 2025
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 31 (14) , 11-19
Functional Limitations and Illness-Related Absenteeism among School-Aged Children with and without Long COVID, United States, 2022–2023
We examined functional limitations and illness-related chronic absenteeism (i.e., missing >18 days of school for health reasons) in a cross-sectional nationally representative sample of 11,057 US children 5-17 years of age who ever or never had long COVID (i.e., symptoms lasting >3 months after COVID-19 illness). Among 4,587 children with prior COVID-19, we estimated whether long COVID was associated with increased illness-related chronic absenteeism by using logistic regression. Our analysis showed that ≈1.4% of school-aged children had long COVID at some point. Among children with prior COVID-19, those who had long COVID at some point more frequently reported functional limitations, such as difficulty with memory, than those who did not have long COVID (18.3% vs. 8.6%). Having long COVID was associated with higher odds of illness-related chronic absenteeism. Children who had long COVID could experience functional limitations and absenteeism. School accommodations might be an option to improve functional limitations.
- 1 January 2025
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 31 (14) , 11-19
Open AccessFunctional Limitations and Illness-Related Absenteeism among School-Aged Children with and without Long COVID, United States, 2022–2023
We examined functional limitations and illness-related chronic absenteeism (i.e., missing >18 days of school for health reasons) in a cross-sectional nationally representative sample of 11,057 US children 5-17 years of age who ever or never had long COVID (i.e., symptoms lasting >3 months after COVID-19 illness). Among 4,587 children with prior COVID-19, we estimated whether long COVID was associated with increased illness-related chronic absenteeism by using logistic regression. Our analysis showed that ≈1.4% of school-aged children had long COVID at some point. Among children with prior COVID-19, those who had long COVID at some point more frequently reported functional limitations, such as difficulty with memory, than those who did not have long COVID (18.3% vs. 8.6%). Having long COVID was associated with higher odds of illness-related chronic absenteeism. Children who had long COVID could experience functional limitations and absenteeism. School accommodations might be an option to improve functional limitations.
- Open Access
- 19 December 2024
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 73 (50) , 1142-1143
Notesfrom the Field: Long COVID and Significant Long COVID–Associated Activity Limitation Among Adults, by Jurisdiction — United States, 2023
This report describes adults with Long COVID and reported limitations performing daily activities.
- 19 December 2024
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 73 (50) , 1142-1143
Open AccessNotesfrom the Field: Long COVID and Significant Long COVID–Associated Activity Limitation Among Adults, by Jurisdiction — United States, 2023
This report describes adults with Long COVID and reported limitations performing daily activities.